Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Astrazeneca Plc (AZN)

52.6   -0.97 (-1.81%) 11-27 01:34
Open: 52.34 Pre. Close: 53.57
High: 53.09 Low: 52.3
Volume: 11,536,903 Market Cap: 136,777M
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); and Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 53.203 - 53.523 53.523 - 53.761
Low: 51.531 - 51.958 51.958 - 52.275
Close: 52.041 - 52.67 52.67 - 53.137

Technical analysis

as of: 2020-11-25 4:35:54 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 64.14     One year: 67.84
Support: Support1: 49.79    Support2: 41.43
Resistance: Resistance1: 54.91    Resistance2: 58.08
Pivot: 55.27
Moving Average: MA(5): 54.04     MA(20): 54.38
MA(100): 54.96     MA(250): 51.64
MACD: MACD(12,26): 0.10     Signal(9): 0.37
Stochastic oscillator: %K(14,3): 20.15     %D(3): 38.55
RSI: RSI(14): 43.05
52-week: High: 64.94  Low: 36.15  Change(%): 8.5
Average Vol(K): 3-Month: 492050  10-Days: 666679

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
AZN has closed above bottom band by 4.7%. Bollinger Bands are 21.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 26 Nov 2020
AstraZeneca faces criticism over COVID-19 vaccine trials results - Proactive Investors UK

Thu, 26 Nov 2020
AstraZeneca Faces More Vaccine Questions After Manufacturing Error - Bloomberg

Mon, 23 Nov 2020
Astra Shot That Works Better in Small Doses Raises Questions - Bloomberg

Mon, 23 Nov 2020
The Chart for AstraZeneca PLC (AZN) Is Flashing Mixed Signals - The News Heater

Mon, 23 Nov 2020
AstraZeneca (AZN)-Oxford Covid-19 Vaccine Prevents Average of 70% of Covid Cases - Bloomberg

Thu, 19 Nov 2020
AstraZeneca Stock Flat Despite Encouraging Vaccine Update - Schaeffers Research

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Neutral Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers General
Shares Out. (M) 2,620
Shares Float (M) 2,620
% Held by Insiders
% Held by Institutions 17.31
Shares Short (K) 6,050
Shares Short P. Month (K) 5,100

Stock Financials

EPS 0.950
EPS Est This Year 1.910
EPS Est Next Year 1.700
Book Value (p.s.) 4.650
Profit Margin 9.65
Operating Margin 19.86
Return on Assets (ttm) 5.2
Return on Equity (ttm) 17.7
Qtrly Rev. Growth 2.7
Gross Profit (p.s.) 7.458
Sales Per Share 9.874
EBITDA (p.s.) 2.939
Qtrly Earnings Growth 116.70
Operating Cash Flow (M) 4,380
Levered Free Cash Flow (M) 4,980

Stock Valuations

PE Ratio 55.37
PEG Ratio 1.33
Price to Book value 11.31
Price to Sales 5.33
Price to Cash Flow 31.46

Stock Dividends

Dividend 2.800
Forward Dividend 1.400
Dividend Yield 0.05
Dividend Pay Date 2020-09-13
Ex-Dividend Date 2020-08-12
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.